Showing 761 - 780 results of 3,563 for search '"antibody"', query time: 0.09s Refine Results
  1. 761

    Antibody response to Plasmodium vivax in the context of Epstein-Barr virus (EBV) co-infection: A 14-year follow-up study in the Amazon rainforest. by Luiz F F Guimarães, Bárbara A Rodrigues, Michelle H F Dias, Matheus G Barcelos, Maria F A Nascimento, Sâmick L Moreira-Nascimento, Sofia L Afonso, Barbara G S Abreu, Jaap M Middeldorp, Francis B Ntumngia, John H Adams, Camila Fabbri, Stefanie Lopes, Cor J F Fernandes, Flora S Kano, Luzia H Carvalho

    Published 2025-01-01
    “…Regardless of the malaria transmission period, the results demonstrated that one or multiple episodes of EBV-DNAemia did not influence the longevity of DBPII immune responses to both strain-specific (Sal-1) or strain-transcending (DEKnull-2) antibodies. Also, the average time in which DBPII-responders lost their antibodies was unrelated to the EBV serostatus. …”
    Get full text
    Article
  2. 762
  3. 763
  4. 764
  5. 765
  6. 766
  7. 767
  8. 768
  9. 769
  10. 770
  11. 771
  12. 772
  13. 773
  14. 774
  15. 775
  16. 776

    The Possible Role of Transplacentally-Acquired Antibodies to Infectious Agents, With Molecular Mimicry to Nervous System Sialic Acid Epitopes, as Causes of Neuromental Disorders: Prevention and Vaccine Implications by André J. Nahmias, Susanne Beckman Nahmias, Dan Danielsson

    Published 2006-01-01
    “…Lessons from four-decade investigations of the epidemiology, immunology, pathogenesis, prevention and therapy of perinatal infectious agents, which invade directly the nervous system, have led us to propose a new indirect effect hypothesis: maternal transplacentally-acquired antibodies, to agents with epitope molecular mimicry with the developing nervous system, can cross the fetus/infant's blood–nervous system barriers to cause NMD's, clinically manifest years later.…”
    Get full text
    Article
  17. 777
  18. 778

    A bioinformatics approach for identifying the probable cause of the cross-interaction of antibodies to the antigenic protein HPV16 L1 with the HPV6 L1 protein by A. S. Stolbikov, R. K. Salyaev, N. I. Rekoslavskaya

    Published 2021-12-01
    “…Consequently, some moderate cross-interaction of the antibodies to HPV16 L1 with the antigens of HPV6 L1 may be expected.…”
    Get full text
    Article
  19. 779

    First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies by Peter Ellmark, Jeffrey Yachnin, Ana Carneiro, Lena Schultz, Amanda Hahn, Sumeet Ambarkhane, Karin Enell Smith, Gustav J. Ullenhag

    Published 2025-01-01
    “…Background ATOR-1017 (evunzekibart) is a human agonistic immunoglobulin G4 antibody targeting the costimulatory receptor 4-1BB (CD137). …”
    Get full text
    Article
  20. 780